Alan Lumsden, MD
Vascular Surgery · Houston, TXNPI 1649350042
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $484,500 of the $741,751 with a category attached, or 65.3%. Corindus Inc. accounts for 66.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $531,329 and has fallen 90.4% since, to $50,859 in 2025. Among vascular surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,140 payments — averaging $650.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corindus Inc.$490K
- Siemens Medical Solutions USA, Inc.$70K
- W. L. Gore & Associates, Inc.$63K
- Boston Scientific$43K
- Endologix LLC$16K
- GE HealthCare$9K
- plus $50K from 54 others
Across 54 payments — averaging $30,241 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$1.5M
- Endologix LLC$101K
- W. L. Gore & Associates, Inc.$40K
- Cook Research Incorporated$19K
- Silk Road Medical, Inc.$3K
What the payments were for
- Consulting fees$83,46511%
- Speaking & faculty fees$51,7307%
- Travel & lodging$70,48010%
- Food & beverage$51,5597%
- Education$170%
- Ownership interest$484,50065%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE VIABAHN Endoprosthesis with Heparin$33,335
- GENERAL - THERAPIES$25,040
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$17,231
- GORE TAG Thoracic Branch Endoprosthesis$17,229
- GORE ACUSEAL Vascular Graft$16,530
- PROPATEN Bioactive Surface$16,530
- Artis Q ceiling$11,241
- ENROUTE Transcarotid Neuroprotection System$10,185
- MAGNETOM Free.Max$9,407
- Indigo System$6,893
- Alto Abdominal Stent Graft System$6,175
- TAG Thoracic Endoprosthesis$5,526
- VIABAHN Endoprosthesis$5,526
- Da Vinci Surgical System$5,234
- ENHANCE Transcarotid Peripheral Access Kit$4,764
- ENROUTE Transcarotid Stent System$4,246
- ENROUTE 0.014 Guidewire$4,246
- GORE VIABAHN VBX Balloon Expandable Endo$3,510
- Product in Development$3,179
- CROSSBOSS$3,000
How this compares
$741,751 in reported general payments places this provider in the 95th percentile of 347 vascular surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $13,678 |
| ClopidogrelClopidogrel Bisulfate | 34 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $13,67816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 vascular surgery providers in Texas.
Other vascular surgery in Houston
- Gustavo OderichHouston$319K
- Jean BismuthHouston$243K
- Ali AzizzadehHouston$181K
- Steven MaximusHouston$140K
- Samuel LeonardHouston$96K
- Charudatta BavareHouston$72K
- Philip AuyangHouston$43K
- Jayer ChungHouston$42K
- Rana AfifiHouston$41K
- Linda leHouston$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.